statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Latest Ratings for LYRA
 DateFirmActionFromTo May 2020B of A SecuritiesInitiates Coverage OnBuy May 2020JefferiesInitiates Coverage OnBuy
 View More Analyst Ratings for LYRA

 View the...

Why Lyra Therapeutics Stock Is Down 93% Today

Lyra Therapeutics shares are trading lower by 93% to $0.30 during Monday's session. The company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.
read more...

The volume for Lyra Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 516% of the 65-Day Volume Moving Average

LYRA's total volume now sits at 2M. The +0.16% price change was insignificant, leaving IBM's price at $6.23...

Lyra Therapeutics (LYRA, $6.13) entered Downtrend as Momentum indicator drops below 0 level on Mar 26, 2024

This indicator may be signaling that LYRA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

The volume for Lyra Therapeutics stock increased for three consecutive days, resulting in a record-breaking daily growth of 187% of the 65-Day Volume Moving Average

LYRA's total volume now sits at 700.8K. The +0.99% average daily price change was insignificant these 3 days, leaving LYRA's price at $6.13...

Lyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS Projections

LYRA Meets Analyst Expectations for Earnings Per Share, Reveals Full Year and Q4 2023 FinancialsRelated Stocks: LYRA...

Lyra Therapeutics files $300M mixed securities shelf

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
LYRA stock results show that Lyra Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth...

Lyra Therapeutics reports Q4 results

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc...

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Volume	638,662.00
52-Wk High	$6.79
52-Wk Low	$0.2532

LYRA Lyra Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals